Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 36
- Registration Number
- NCT00633529
- Locations
- 🇺🇸
Cancer Centers of Florida, Ocoee, Florida, United States
🇺🇸Central Indiana Cancer Centers, Indianapolis, Indiana, United States
🇺🇸New York Oncology Hematology P.C., Albany, New York, United States
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 461
- Registration Number
- NCT00624338
- Locations
- 🇺🇸
Division of Clinical Immunology and Rheumatology - UAB, Birmingham, Alabama, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇬🇧Research Site, Manchester, United Kingdom
Atacicept in Subjects With Optic Neuritis
- Conditions
- Optic Neuritis
- Interventions
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 34
- Registration Number
- NCT00624468
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 311
- Registration Number
- NCT00595413
- Locations
- 🇺🇸
Please Contact US Medical Information, Rockland, Massachusetts, United States
🇩🇪Please contact the Merck KGaA Communication Center, Darmstadt, Germany
The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 6
- Registration Number
- NCT00573157
- Locations
- 🇺🇸
Tulane University Hospital and Clinic Department of Internal Medicine, New Orleans,, Louisiana, United States
🇺🇸Northwest Louisiana Nephrology Research, Shreveport, Louisiana, United States
🇺🇸Wayne State University Lupus Database Departments of Internal Medicine and Obstetrics & Gynecology Division of Rheumatology Wayne State University School of Medicine, Detroit, Michigan, United States
Growth Hormone in the Treatment of HIV-Associated Wasting
- Conditions
- HIV InfectionsHIV Wasting Syndrome
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- EMD Serono
- Registration Number
- NCT00489528
Rebif New Formulation (RNF) Quality of Life (QOL) Study
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-05-14
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 232
- Registration Number
- NCT00472797
- Locations
- 🇺🇸
EMD Serono, Inc., Rockland, Massachusetts, United States
A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 256
- Registration Number
- NCT00430495
- Locations
- 🇺🇸
EMD Serono, Rockland, Massachusetts, United States
🇨🇦Merck/Serono, Canada, Canada
RNF and Betaseron® Tolerability Study
- Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS)
- Interventions
- Drug: New Formulation of rebif - human interferon beta-1aDrug: Interferon beta -1b
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 129
- Registration Number
- NCT00428584
- Locations
- 🇺🇸
EMD Serono Med Info, Rockland, Massachusetts, United States
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 1513
- Registration Number
- NCT00409188
- Locations
- 🇺🇸
Saint Edward Mercy Medical Center, Fort Smith, Arkansas, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
🇺🇸Glendale Adventist Medical Center, Glendale, California, United States